On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC

Abstract Patients with high-risk non-muscle invasive bladder cancer (NMIBC) are generally treated with transurethral resection of the bladder tumor followed by intravesical bacillus Calmette-Guérin (BCG), the current standard of care. However, recurrence or progression is common and may result in pa...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Oncology and Therapy
المؤلفون الرئيسيون: Bernadett E. Szabados, Félix Guerrero-Ramos, Enrique Grande, Petros Grivas, Viktor Grünwald, Marta Carpintero Miguel, Syed A. Hussain, Girish S. Kulkarni, Ana Lisa Wilson, Neal D. Shore, Srikala S. Sridhar, Mary Hoyt, Samantha Strumeier, Jennifer Sutton, Julia Brinkmann, Rosemary E. Teresi, Tilman Todenhöfer
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Adis, Springer Healthcare 2025-04-01
الموضوعات:
BCG-naïve
Immune checkpoint inhibitor
Medical oncologist
Multidisciplinary
Non-muscle invasive bladder cancer
Nurse
الوصول للمادة أونلاين:https://doi.org/10.1007/s40487-025-00334-6

الانترنت

https://doi.org/10.1007/s40487-025-00334-6

مواد مشابهة